文献速递重症综合管理与镇静镇痛心脑血管急症

COVID-19患者神经损伤生物标志物的比较评估与预后价值:一项前瞻性研究

COMPARATIVE EVALUATION AND PROGNOSTIC UTILITY OF NEURONAL INJURY BIOMARKERS IN COVID-19 PATIENTS: A PROSPECTIVE STUDY.
PubMed 文献 · Shock · 2022-10-21
一句话结论在COVID-19患者中,S100b对ICU死亡的预测能力最佳,AUC为0.73(0.61-0.83),P=0.0003。

该前瞻性观察研究纳入70例COVID-19患者,其中危重症患者入住ICU、中/重症患者入住病房,入院时检测S100b、神经元特异性烯醇化酶(NSE)及炎症标志物(包括可溶性尿激酶纤溶酶原激活物受体suPAR)。以死亡为分类变量、入院生物标志物水平为预后变量绘制ROC曲线,S100b对ICU死亡的预测能力最佳,AUC为0.73(0.61-0.83),P=0.0003。S100b与NSE、白细胞介素(IL)-8、IL-10相关(0.27<rs<0.37,P<0.05),与suPAR趋于相关(rs=0.26,P=0.05),与血管加压药剂量无关(P=0.62)。作者认为整体生物标志物谱提示新型冠状病毒直接累及神经系统。

要点

  • 在70例COVID-19患者中,S100b对ICU死亡的预测能力最佳,AUC 0.73(0.61-0.83),P=0.0003。
  • S100b与NSE、IL-8、IL-10相关(0.27<rs<0.37,P<0.05),与suPAR趋于相关(rs=0.26,P=0.05)。
  • S100b与血管加压药剂量无关(P=0.62)。
  • 作者认为整体生物标志物谱提示新型冠状病毒直接累及神经系统。

适用人群与场景

  • 危重症COVID-19患者入住ICU,中/重症COVID-19患者入住病房,分别在ICU或病房入院时检测生物标志物。

研究设计与关键结果

  • 前瞻性观察研究,最终分析纳入70例COVID-19患者。
  • 在ICU中,S100b对死亡的预测能力最佳,AUC为0.73(0.61-0.83),P=0.0003。
  • S100b与NSE、IL-8、IL-10相关(0.27<rs<0.37,P<0.05),与suPAR趋于相关(rs=0.26,P=0.05),与血管加压药剂量无关(P=0.62)。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在所研究的生物标志物中,S100b对COVID-19患者死亡的预测能力最佳。
  • 作者认为,患者的整体生物标志物谱提示新型冠状病毒直接累及神经系统。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background : COVID-19 disease severity markers include mostly molecules related to not only tissue perfusion, inflammation, and thrombosis, but also biomarkers of neural injury. Clinical and basic research has demonstrated that SARS-COV-2 affects the central nervous system. The aims of the present study were to investigate the role of neural injury biomarkers and to compare them with inflammatory markers in their predictive ability of mortality. Methods : We conducted a prospective observational study in critically ill patients with COVID-19 and in a cohort of patients with moderate/severe disease. S100b, neuron-specific enolase (NSE), and inflammatory markers, including soluble urokinase plasminogen activator receptor (suPAR), were measured on intensive care unit or ward admission, respectively. Statistical comparisons between patient groups were performed for all biomarkers under investigation. Correlations between different biomarkers were tested with Spearman correlation coefficient. Receiver operating characteristic curves were plotted using mortality as the classification variable and the biomarker levels on admission as the prognostic variables. Results : A total of 70 patients with COVID-19 were included in the final analysis. Of all studied biomarkers, s100b had the best predictive ability for death in the intensive care unit, with an area under the curve of 0.73 (0.61-0.83), P = 0.0003. S100b levels correlated with NSE, interleukin (IL)-8, and IL-10 (0.27 < rs < 0.37, P < 0.05), and tended to correlate with suPAR ( rs = 0.26, P = 0.05), but not with the vasopressor dose ( P = 0.62). Conclusion : Among the investigated biomarkers, s100b demonstrated the best predictive ability for death in COVID-19 patients. The overall biomarker profile of the patients implies direct involvement of the nervous system by the novel coronavirus.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Vrettou CS, Vassiliou AG, Pratikaki M, et al. COMPARATIVE EVALUATION AND PROGNOSTIC UTILITY OF NEURONAL INJURY BIOMARKERS IN COVID-19 PATIENTS: A PROSPECTIVE STUDY. Shock. 2022. PMID: 36548642. doi:10.1097/SHK.0000000000002017

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。